445 related articles for article (PubMed ID: 9801258)
1. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
Hershfield MS
Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow gene therapy for adenosine deaminase deficiency.
Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
[TBL] [Abstract][Full Text] [Related]
4. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
5. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y
Hokkaido Igaku Zasshi; 1996 Jan; 71(1):27-32. PubMed ID: 8727372
[TBL] [Abstract][Full Text] [Related]
6. Management options: SCIDS with adenosine deaminase deficiency.
Hilman BC; Sorensen RU
Ann Allergy; 1994 May; 72(5):395-403; quiz 403-4, 407. PubMed ID: 8179225
[TBL] [Abstract][Full Text] [Related]
7. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
[TBL] [Abstract][Full Text] [Related]
8. Adenosine deaminase deficiency.
Hirschhorn R
Immunodefic Rev; 1990; 2(3):175-98. PubMed ID: 2078332
[TBL] [Abstract][Full Text] [Related]
9. Severe combined immunodeficiency of reduced severity due to homozygosity for an adenosine deaminase missense mutation (Arg253Pro).
Hirschhorn R; Yang DR; Insel RA; Ballow M
Cell Immunol; 1993 Dec; 152(2):383-93. PubMed ID: 8258146
[TBL] [Abstract][Full Text] [Related]
10. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.
Carbonaro DA; Jin X; Petersen D; Wang X; Dorey F; Kil KS; Aldrich M; Blackburn MR; Kellems RE; Kohn DB
Mol Ther; 2006 Jun; 13(6):1110-20. PubMed ID: 16651028
[TBL] [Abstract][Full Text] [Related]
11. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
12. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
13. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y; Ariga T; Ohtsu M
Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
[TBL] [Abstract][Full Text] [Related]
14. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
15. [The gene therapy for a patient with ADA deficiency; report of the first gene therapy trial in Japan].
Ariga T; Kawamura N; Sakiyama Y
Nihon Rinsho; 1997 Jun; 55(6):1572-9. PubMed ID: 9200950
[TBL] [Abstract][Full Text] [Related]
16. Visible integration of the adenosine deaminase (ADA) gene into the recipient genome after gene therapy.
Egashira M; Ariga T; Kawamura N; Miyoshi O; Niikawa N; Sakiyama Y
Am J Med Genet; 1998 Jan; 75(3):314-7. PubMed ID: 9475605
[TBL] [Abstract][Full Text] [Related]
17. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
[TBL] [Abstract][Full Text] [Related]
18. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
Chun JD; Lee N; Kobayashi RH; Chaffee S; Hershfield MS; Stiehm ER
Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
[TBL] [Abstract][Full Text] [Related]
19. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
Silver JN; Flotte TR
Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
[TBL] [Abstract][Full Text] [Related]
20. Hyperbilirubinemia and rapid fatal hepatic failure in severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID).
Kühl JS; Schwarz K; Münch A; Schmugge M; Pekrun A; Meisel C; Wahn V; Ebell W; von Bernuth H
Klin Padiatr; 2011 Mar; 223(2):85-9. PubMed ID: 21271505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]